PE20180035A1 - Tableta de ribociclib - Google Patents
Tableta de ribociclibInfo
- Publication number
- PE20180035A1 PE20180035A1 PE2017002096A PE2017002096A PE20180035A1 PE 20180035 A1 PE20180035 A1 PE 20180035A1 PE 2017002096 A PE2017002096 A PE 2017002096A PE 2017002096 A PE2017002096 A PE 2017002096A PE 20180035 A1 PE20180035 A1 PE 20180035A1
- Authority
- PE
- Peru
- Prior art keywords
- ribociclib
- tablet
- reibociclib
- piperazin
- pyrrolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148240P | 2015-04-16 | 2015-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180035A1 true PE20180035A1 (es) | 2018-01-09 |
Family
ID=55806565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002096A PE20180035A1 (es) | 2015-04-16 | 2016-04-14 | Tableta de ribociclib |
Country Status (29)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017013350A (es) * | 2015-04-16 | 2018-01-25 | Novartis Ag | Comprimido de ribociclib. |
| CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Novel crystalline form of ribociclib succinate |
| AU2020336309A1 (en) | 2019-08-26 | 2022-03-17 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CR20220342A (es) | 2019-12-16 | 2023-01-23 | Lunella Biotech Inc | Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 |
| US12358920B2 (en) | 2019-12-16 | 2025-07-15 | Lunella Biotech, Inc. | Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors |
| BR112023001454A2 (pt) * | 2020-08-03 | 2023-02-14 | Natco Pharma Ltd | Composição de comprimido de liberação imediata e processo para a preparação da composição |
| MX2022015336A (es) * | 2020-09-29 | 2023-01-11 | Laboratorios Silanes S A De C V | Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares. |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| AU2022311961A1 (en) | 2021-07-16 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
| TWI848533B (zh) | 2022-01-25 | 2024-07-11 | 瑞士商諾華公司 | 瑞博西尼藥物組成物 |
| JP2025530742A (ja) | 2022-08-31 | 2025-09-17 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体分解物質の投与計画 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| KR20250163966A (ko) | 2023-03-27 | 2025-11-21 | 노파르티스 아게 | 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법 |
| WO2025219830A1 (en) | 2024-04-15 | 2025-10-23 | Novartis Ag | Pharmaceutical compositions of ribociclib |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5428812A (en) * | 1977-08-09 | 1979-03-03 | Yoshitomi Pharmaceut Ind Ltd | Preparation of coated tablet |
| GB9414045D0 (en) | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| AU703933B2 (en) * | 1994-07-12 | 1999-04-01 | Berwind Pharmaceutical Services, Inc. | Moisture barrier film coating composition, method, and coated form |
| US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| BRPI0917791B1 (pt) | 2008-08-22 | 2022-03-22 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação |
| US8807979B2 (en) * | 2009-09-24 | 2014-08-19 | Mcneil-Ppc, Inc. | Machine for the manufacture of dosage forms utilizing radiofrequency energy |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| AU2011358840B2 (en) * | 2011-02-11 | 2017-05-04 | TauRx Therapeutics Management Ltd | Phenothiazine diaminium salts and their use |
| LT2872482T (lt) * | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
| ES2676177T3 (es) * | 2012-12-20 | 2018-07-17 | Novartis Ag | Una combinación farmacéutica que comprende binimetinib |
| AU2014233805B2 (en) * | 2013-03-21 | 2018-10-18 | Array Biopharma Inc. | Combination therapy comprising a B-Raf inhibitor and a second inhibitor |
| EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| MX2017013350A (es) * | 2015-04-16 | 2018-01-25 | Novartis Ag | Comprimido de ribociclib. |
| CN109953966A (zh) * | 2017-12-26 | 2019-07-02 | 天津耀辰实业发展有限公司 | 一种含有瑞博西尼的药物组合物及其制备方法 |
| JP7347388B2 (ja) | 2020-09-25 | 2023-09-20 | 信越化学工業株式会社 | 紫外線硬化型有機変性シリコーン組成物および硬化物 |
-
2016
- 2016-04-14 MX MX2017013350A patent/MX2017013350A/es unknown
- 2016-04-14 HU HUE16718020A patent/HUE061213T2/hu unknown
- 2016-04-14 AU AU2016248017A patent/AU2016248017A1/en not_active Abandoned
- 2016-04-14 KR KR1020257000051A patent/KR20250009572A/ko active Pending
- 2016-04-14 CN CN201680022122.8A patent/CN107530292B/zh active Active
- 2016-04-14 AR ARP160101012A patent/AR104257A1/es unknown
- 2016-04-14 US US15/564,534 patent/US10799506B2/en active Active
- 2016-04-14 EP EP25194967.3A patent/EP4620458A3/en active Pending
- 2016-04-14 PL PL16718020.7T patent/PL3283058T3/pl unknown
- 2016-04-14 EA EA201792290A patent/EA201792290A1/ru unknown
- 2016-04-14 SI SI201631661T patent/SI3283058T1/sl unknown
- 2016-04-14 EP EP16718020.7A patent/EP3283058B1/en active Active
- 2016-04-14 JP JP2017553915A patent/JP2018514523A/ja active Pending
- 2016-04-14 FI FIEP16718020.7T patent/FI3283058T3/fi active
- 2016-04-14 EP EP22203730.1A patent/EP4197530B1/en active Active
- 2016-04-14 PT PT167180207T patent/PT3283058T/pt unknown
- 2016-04-14 PE PE2017002096A patent/PE20180035A1/es unknown
- 2016-04-14 BR BR112017021283A patent/BR112017021283A2/pt not_active Application Discontinuation
- 2016-04-14 KR KR1020177029433A patent/KR102750931B1/ko active Active
- 2016-04-14 ES ES16718020T patent/ES2938261T3/es active Active
- 2016-04-14 SG SG11201708084PA patent/SG11201708084PA/en unknown
- 2016-04-14 TN TNP/2017/000422A patent/TN2017000422A1/en unknown
- 2016-04-14 CA CA2982425A patent/CA2982425C/en active Active
- 2016-04-14 CN CN202211237232.XA patent/CN115554257A/zh active Pending
- 2016-04-14 HR HRP20230053TT patent/HRP20230053T1/hr unknown
- 2016-04-14 DK DK16718020.7T patent/DK3283058T3/da active
- 2016-04-14 WO PCT/IB2016/052136 patent/WO2016166703A1/en not_active Ceased
- 2016-04-15 TW TW105111921A patent/TW201642864A/zh unknown
-
2017
- 2017-10-01 IL IL254818A patent/IL254818A0/en unknown
- 2017-10-04 PH PH12017501820A patent/PH12017501820A1/en unknown
- 2017-10-13 CO CONC2017/0010510A patent/CO2017010510A2/es unknown
- 2017-10-13 CL CL2017002593A patent/CL2017002593A1/es unknown
- 2017-11-10 EC ECIEPI201775052A patent/ECSP17075052A/es unknown
-
2019
- 2019-03-20 AU AU2019201929A patent/AU2019201929B2/en active Active
-
2020
- 2020-08-26 US US17/003,771 patent/US20200390771A1/en not_active Abandoned
- 2020-10-06 AU AU2020250190A patent/AU2020250190A1/en not_active Abandoned
-
2022
- 2022-06-08 US US17/805,956 patent/US12064434B2/en active Active
- 2022-08-08 AU AU2022215155A patent/AU2022215155B2/en active Active
-
2024
- 2024-02-27 US US18/588,259 patent/US20250090531A1/en active Pending
- 2024-10-31 AU AU2024227794A patent/AU2024227794A1/en active Pending
- 2024-12-11 US US18/977,228 patent/US12419894B2/en active Active
- 2024-12-11 US US18/977,210 patent/US20250134893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180035A1 (es) | Tableta de ribociclib | |
| ECSP21014448A (es) | Sales de inhibidor de pi3k y procesos de preparación | |
| DOP2015000206A (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas janus (jak) | |
| UY37781A (es) | Proceso para la preparación de pirazolo[1,5-a] pirimidinas y sales de las mismas | |
| JO3670B1 (ar) | ملح سكسينات من 7-سيكلوبنتيل -2- (5-بيبرازين-1-يل-بيريدين-2-يل أمينو) -7h-بيرولو [2، 3-d] بيريميدين -6-ثنائي ميثيل أميد حمض الكربوكسيل وعمليات تصنيعه | |
| MX2015016513A (es) | Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo. | |
| EP3172214A4 (en) | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof | |
| EA201890820A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
| BR112013019223A2 (pt) | forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral | |
| CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
| GT201400196A (es) | Compuestos de heterociclilo | |
| CO6741203A2 (es) | Derivados de biciclo[3,2,1]octilamida y sus usos | |
| MX2019008815A (es) | Sintesis de un inhibidor de tirosina quinasa de bruton. | |
| MX386584B (es) | Composiciones de liberación retardada de linaclotida. | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| CO2019012571A2 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| MX2020004148A (es) | Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| GT201500292A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
| EP3196199A4 (en) | Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor | |
| CU20150176A7 (es) | Derivados de prodroga de triazolpiridinas sustituídas | |
| ES2502140T1 (es) | Comprimidos de liberación inmediata de rasagilina hemitartrato | |
| MX2018009758A (es) | Uso de inhibidores de la actividad o funcion de pi3k para el tratamiento del sindrome primario de sjögren. | |
| TH1501004773A (th) | อนุพันธ์ไพร์โรโล[2,3-d]ไพริมิดีนเป็นที่สารยับยั้งของไคเนสที่สัมพันธ์กับเจนัส (jak) |